Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Martin Edelman MD
Mediastinal nodal clearance following completion of induction chemoradiation +/- panitumumab
Pathologically proven diagnosis Stage IIIA (T1-T3) with a single primary lung parenchymal lesion and N2 positive ipsilateral mediastinal nodes
Data for this trial is being collected via the NRG/RTOG Data Center.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.